January 18, 2022
Bimekizumab, an interleukin 17A (IL-17A) and IL-17F inhibitor, met both primary and secondary endpoints for treating adult patients with non-radiographic axial spondyloarthritis.
December 09, 2021
Jessica Walsh, MD, explains the importance of understanding treatment satisfaction and decision-making in patients with axial spondyloarthritis based on patient-reported outcomes.
October 26, 2021
Chronic back pain, a common symptom of axial spondyloarthritis that increases disease burden and reduces quality of life, may be improved by subcutaneous injection of secukinumab 150 mg or 300 mg.
October 08, 2021
Upadacitinib achieved positive results from both Phase 3 SELECT-AXIS clinical trials, which focused on patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis.
October 07, 2021
Limited information is available on the overall disease burden of axial spondyloarthritis (axSpA) in women, as they are generally underrepresented in clinical studies.
October 05, 2021
“Many patients with axial spondyloarthritis who receive treatment still experience disease-related burdens in different aspects of health-related quality of life,” investigators stated.
August 31, 2021
"Physical activity and exercise have been shown to improve general well-being and reduce cardiovascular disease risk in the general population," investigators stated. "Despite these recommendations, studies show that levels of PA are reduced among patients with axial spondyloarthritis.”
August 24, 2021
The Epionics SPINE is an innovative tool to assess the spinal mobility of patients with axial spondyloarthritis.
June 15, 2021
Jeffrey Stark, MD, discusses the statement UCB issued endorsing the creation of a new sub-category (M.45A) for non-radiographical axial spondyloarthritis (nr-axSpA).
June 09, 2021
Rheumatology Network spoke with Jessica Walsh, MD, to discuss her study, “Patient perspectives of biologic treatments for axial spondyloarthritis: satisfaction, wear-off between doses, and use of supplemental medications."